利妥昔单抗治疗成人复发性肾病综合征:一项随机临床试验
这项在日本13个中心开展的多中心、双盲、随机、安慰剂对照试验纳入72例成人频复发或激素依赖性肾病综合征患者,比较静脉利妥昔单抗375 mg/m²与安慰剂的疗效。第49周无复发率利妥昔单抗组为87.4%,安慰剂组为38.0%(P<.001),复发风险比为0.16,支持使用利妥昔单抗预防复发。
要点
- 第49周无复发率利妥昔单抗组87.4% vs 安慰剂组38.0%(P<.001)。
- 利妥昔单抗组复发风险比为0.16(95%CI 0.05-0.46;P<.001)。
- 最常见不良事件为输液反应,利妥昔单抗组13例(40.6%)vs 安慰剂组1例(2.9%)。
核心结论
- 这些结果支持使用利妥昔单抗预防成人频复发或激素依赖性肾病综合征患者的复发。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照试验,在日本13个中心开展。
- 纳入尿蛋白低于0.3 g/gCr的成人频复发或激素依赖性肾病综合征患者,2020年9月1日至2022年6月28日入组,末次随访2024年3月15日。
- 患者随机接受静脉利妥昔单抗375 mg/m²(n=36)或安慰剂(n=36),于第1、2、25周给药,随访49周。
- 72例随机参与者(平均年龄47.9岁;女性56.1%)中,66例(92%)至少接受一次研究药物并纳入分析。
主要发现
- 第49周无复发率利妥昔单抗组为87.4%(95%CI 69.8%-95.1%),安慰剂组为38.0%(95%CI 22.1%-53.8%)(单侧对数秩检验P<.001)。
- 18个次要结局中有1个具有统计学显著性(有利于利妥昔单抗)。
- 无复发时间中位数利妥昔单抗组大于49.0周,安慰剂组为30.8周。
- 分层Cox模型显示,与安慰剂组相比,利妥昔单抗组复发风险比为0.16(95%CI 0.05-0.46;P<.001)。
- 最常见不良事件为输液反应,利妥昔单抗组13例(40.6%),安慰剂组1例(2.9%)。
关键数值与推荐
- 复发定义为连续2次测量尿蛋白至少1 g/gCr。
临床怎么用
- 这些结果支持使用利妥昔单抗预防成人频复发或激素依赖性肾病综合征患者的复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effects of rituximab on relapse of nephrotic syndrome in patients with adult-onset frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) remain uncertain. OBJECTIVE: To evaluate the effects of rituximab for patients with FRNS or SDNS. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized, placebo-controlled trial conducted at 13 centers in Japan. Adults with FRNS or SDNS who had urine protein of less than 0.3 g/gCr were enrolled between September 1, 2020, and June 28, 2022. Final follow-up occurred on March 15, 2024. INTERVENTIONS: Patients were randomized to receive either intravenous rituximab, 375 mg/m2 (n = 36), or placebo (n = 36) at weeks 1, 2, and 25. Patients were followed up for 49 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients who were free of relapse of nephrotic syndrome at 49-week follow-up. Relapse was defined as urine protein of at least 1 g/gCr on 2 consecutive measurements. RESULTS: Among 72 randomized participants (mean age, 47.9 years; 56.1% female), 66 (92%) received the study drug at least once and were included in analyses. The relapse-free rate at week 49 was 87.4% (95% CI, 69.8%-95.1%) in the rituximab group and 38.0% (95% CI, 22.1%-53.8%) in the placebo group (P < .001 by 1-sided log-rank test). One of 18 secondary outcomes was statistically significant (favoring rituximab). The median relapse-free time in the rituximab group was greater than 49.0 weeks and in the placebo group was 30.8 weeks. A stratified Cox model showed a hazard ratio for relapse of 0.16 (95% CI, 0.05-0.46; P < .001) in the rituximab group compared with the placebo group. The most common adverse effect was infusion reaction (13 [40.6%] in the rituximab group and 1 [2.9%] in the placebo group). CONCLUSIONS AND RELEVANCE: These results support use of rituximab to prevent relapse in adults with FRNS or SDNS. TRIAL REGISTRATION: Japan Registry of Clinical Trials: jRCT2051200045; University Hospital Medical Information Network Clinical Trials Registry: UMIN000041475.
引用
- Isaka Y, Sakaguchi Y, Shinzawa M, et al. Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial. JAMA. 2025. PMID: 41191364. doi:10.1001/jama.2025.19316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。